Jefferies Financial Group Inc. Invests $477,000 in TG Therapeutics, Inc. $TGTX

Jefferies Financial Group Inc. acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 16,000 shares of the biopharmaceutical company’s stock, valued at approximately $477,000.

Several other large investors have also modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of TG Therapeutics by 1.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company’s stock worth $1,135,000 after acquiring an additional 441 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of TG Therapeutics by 21.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 2,693 shares of the biopharmaceutical company’s stock worth $99,000 after acquiring an additional 467 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 486 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in shares of TG Therapeutics by 1.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,062 shares of the biopharmaceutical company’s stock worth $926,000 after acquiring an additional 500 shares in the last quarter. Finally, Lido Advisors LLC boosted its stake in shares of TG Therapeutics by 3.9% during the 3rd quarter. Lido Advisors LLC now owns 14,276 shares of the biopharmaceutical company’s stock worth $516,000 after acquiring an additional 541 shares in the last quarter. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Price Performance

TGTX opened at $37.94 on Friday. The stock has a fifty day moving average of $36.21 and a 200-day moving average of $32.31. The firm has a market capitalization of $5.81 billion, a P/E ratio of 13.27 and a beta of 1.68. TG Therapeutics, Inc. has a 12-month low of $25.28 and a 12-month high of $44.65. The company has a quick ratio of 5.12, a current ratio of 5.81 and a debt-to-equity ratio of 1.28.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The business had revenue of $204.92 million during the quarter, compared to analysts’ expectations of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. TG Therapeutics’s revenue for the quarter was up 69.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.03 EPS. Equities analysts forecast that TG Therapeutics, Inc. will post 1.31 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TGTX. Wall Street Zen lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. JPMorgan Chase & Co. reduced their target price on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of TG Therapeutics in a report on Wednesday. Finally, Zacks Research lowered TG Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.50.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.